Now Reading: Gland Pharma to Add 1,400-Tonne Sterile API Capacity for Neuland
-
01
Gland Pharma to Add 1,400-Tonne Sterile API Capacity for Neuland
Gland Pharma to Add 1,400-Tonne Sterile API Capacity for Neuland
Gland Pharma will build and operate a dedicated sterile manufacturing suite at its Visakhapatnam facility for Neuland Laboratories under a long-term contract development and manufacturing partnership. The suite is expected to add…
The Story in Brief
Gland Pharma will build and operate a dedicated sterile manufacturing suite at its Visakhapatnam facility for Neuland Laboratories under a long-term contract development and manufacturing partnership. The suite is expected to add about 1,400 kg of annual capacity and will meet current good manufacturing practice, US FDA and EU standards.
The companies will jointly provide development, scale-up, regulatory support and commercial manufacturing for sterile active pharmaceutical ingredients, including those used in microparticle depot products and other complex injectable therapies. Neuland’s board has approved a deed of corporate guarantee worth Rs 40 crore in favour of Gland Pharma. The partnership combines Neuland’s complex API capabilities with Gland Pharma’s sterile manufacturing and regulatory expertise.
The Indian Opinion
Claims that this is either a routine outsourcing deal or an instant export breakthrough would both overstate the facts. The immediate outcome is a planned facility and added capacity, not confirmed sales or commercial production. Its value will depend on construction, regulatory compliance and actual customer orders for sterile APIs. The clearest test is whether the promised 1,400 kg capacity becomes operational and generates sustained revenue.
Source: thehindu.com
This story was synthesised by AI from the source linked above.
